Abstract: Chemotherapy(CT) and endocrine therapy (ET) both are major and important systematic treatments for breast cancer. In the clinical practice, the clinicians prefer to afford CT followed by ET rather than concurrent CT and ET to early or advanced hormone receptor-positive breast cancer patients, regardless of menstrual state or regimen. There is no consensus about the efficacy and safety of concurrent CT and ET. Previous trials showed that the concurrent CT and ET is not beneficial, even contrary. However, some recent studies showed that the concurrent CT and ET may significantly improve the survival of breast cancer patients, which is worth more researches.